To this aim, we tested in the present study the sensitivity of 8 PDX models, comprising 7 TNBC (2 BRCA1-WT, 4 BRCA1-methylated (BRCA1-Me), 1 BRCA1-Mut) and 1 BRCA1-Mut High Grade Ovarian Serous Ovarian Carcinoma (HGSOC), to the PARP inhibitor olaparib and to carboplatin (CBP). The gene discussed is PARP1; the disease is ovarian serous carcinoma.